Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas C Marchion

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Cancer Research|May 31, 2002
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathwayPamela N Münster, Douglas C Marchion, Andrea D Basso, et al.
Cancer Research|March 5, 2008
Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signalingElona Biçaku, Douglas C Marchion, Morgen L Schmitt, et al.
Cancer Research|May 23, 2014
Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput dataJesus Gonzalez Bosquet, Douglas C Marchion, HyeSook Chon, et al.
Breast Cancer Research and Treatment|February 8, 2011
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagyScott Thomas, Kenneth T Thurn, Elona Biçaku, et al.
Cancer Research|May 4, 2005
Valproic acid alters chromatin structure by regulation of chromatin modulation proteinsDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Molecular Cancer Therapeutics|December 24, 2005
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Tissue Engineering|September 15, 2004
Halofuginone inhibits serum-stimulated pericardial tissue retraction in vitroDouglas C Marchion, Patricia A Weber, Liat Lomnitski, et al.
Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Molecular Cancer Therapeutics|April 18, 2009
HDAC2 regulates chromatin plasticity and enhances DNA vulnerabilityDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Cancer Research|May 31, 2002
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathwayPamela N Münster, Douglas C Marchion, Andrea D Basso, et al.
Cancer Research|March 5, 2008
Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signalingElona Biçaku, Douglas C Marchion, Morgen L Schmitt, et al.
Cancer Research|May 23, 2014
Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput dataJesus Gonzalez Bosquet, Douglas C Marchion, HyeSook Chon, et al.
Breast Cancer Research and Treatment|February 8, 2011
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagyScott Thomas, Kenneth T Thurn, Elona Biçaku, et al.
Cancer Research|May 4, 2005
Valproic acid alters chromatin structure by regulation of chromatin modulation proteinsDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Molecular Cancer Therapeutics|December 24, 2005
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlatesDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Tissue Engineering|September 15, 2004
Halofuginone inhibits serum-stimulated pericardial tissue retraction in vitroDouglas C Marchion, Patricia A Weber, Liat Lomnitski, et al.
Journal of Cellular Biochemistry|April 27, 2004
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acidDouglas C Marchion, Elona Bicaku, Adil I Daud, et al.
Molecular Cancer Therapeutics|April 18, 2009
HDAC2 regulates chromatin plasticity and enhances DNA vulnerabilityDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2005
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbetaDouglas C Marchion, Elona Bicaku, Joel G Turner, et al.
Pageof 4